Korro Bio (KRRO) Operating Expenses (2018 - 2026)

On a trailing twelve-month basis, Korro Bio's Operating Expenses was $112.56 million through Jun 30, 2026, up 7.4% year-over-year; for FY2025, it came in at $128.25 million, up 36.2% from FY2024.

• Operating Expenses has now increased for three consecutive years, with a five-year compound annual growth rate of 14.7% (FY2020 to FY2025).
• In earlier years, Operating Expenses was $94.18 million in FY2024 (+11.4%), $84.53 million in FY2023 (+43.3%), $59 million in FY2022 (-39.9%) and $98.1 million in FY2021 (+52.0%).
• The Q2 2026 figure marks the lowest quarterly Operating Expenses since Q3 2023.
• Compared with a year earlier, Operating Expenses was higher in four of the last eight quarters, with growth averaging 12.4%.
• The best year-over-year quarter for Operating Expenses over five years was Q4 2025 (growth of 104.2%); the worst was Q2 2026 (a decline of 29.8%).
• Per Business Quant data, KRRO's Operating Expenses in the three quarters before Q2 2026 was $20.44 million (Q1 2026), $51.69 million (Q4 2025) and $20.33 million (Q3 2025).